Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Recent research suggests that dietary fructose intake may increase serum uric acid concentrations and that both uric acid concentration and fructose consumption may be increased in individuals with non-alcoholic fatty liver disease.
Although one of the most serious complications of cirrhosis is liver cancer, or hepatocellular carcinoma (HCC), an analysis of health records revealed that the 10-year incidence of HCC in UK patients with cirrhosis is four percent or lower.
Scientists have shed new light on how the common painkiller paracetamol causes liver damage.
Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus
Non-alcoholic fatty liver disease has become a global epidemic. There is not only a great interest worldwide to understand the causes and consequences of fatty liver disease, but also to diagnose fatty liver disease at an early stage.
Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient’s response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is significant because it may help physicians tailor more effective treatments for the up to 2.2 million individuals infected with HBV.
Use of an advanced form of the commonly used polymerase chain reaction (PCR) method to analyze circulating tumor cells (CTCs) may greatly increase the ability to diagnose early-stage cancer, increasing the likelihood of successful treatment.
A team of Michigan State University researchers, led by James Luyendyk in the College of Veterinary Medicine, has uncovered a new pathway in the body that stimulates liver repair.
This condition generally leads to chronic inflammation (non-alcoholic steatohepatitis), which can trigger fibrosis, cirrhosis and ultimately liver cancer. This study on the basic biology of the liver paves the way to examine therapeutic strategies to fight and prevent fatty liver disease.
Mice with a strong tendency to obesity already exhibit epigenetic changes at six weeks of age, inducing the liver to amplify its production of the enzyme DPP4 and release it into the circulation. Over the long term, this favors the development of a fatty liver.
Researchers from the University of South Carolina, Duke University, University of Alabama at Birmingham, and Metabolon Inc. Research Triangle Park have discovered a new pathway in the liver that opens the door to treat non-alcoholic fatty liver disease, a condition that affects up to 25 percent of the population and may lead to cirrhosis and eventually liver cancer or failure, and likely other liver diseases.
Newcastle scientists and medics have developed a promising new test to identify patients with a rare liver disease who will not respond to standard treatment, allowing earlier intervention with alternatives.
More than 1,000 medications, with acetaminophen being the most common, have been associated with drug-induced liver injury.
The innate immune system in mammals defends against infection from viruses and other microbial infections.
"One drink a day might be too much for a woman who has a genetic pre-disposition to cirrhosis of the liver," said Howard Monsour, M.D., chief of hepatology at Houston Methodist Hospital "One drink for a woman has about twice the effect as it does for the same amount consumed by a man."
Non-alcoholic steatohepatitis (NASH) is a potentially serious liver condition characterized by excess fat in the liver associated with inflammation and scarring.
Proactive outreach to cirrhosis patients in a safety net health system successfully doubled their screening rates for liver cancer, UT Southwestern Medical Center researchers found.
The virus that causes hepatitis C protects itself by blocking signals that call up immune defenses in liver cells, according to University of Washington researchers and colleagues reporting Nov. 14 in Nature Medicine.
A new study presented this week at The Liver Meeting — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication.
According to a new nutritional study conducted by the German Institute of Human Nutrition on individuals with type 2 diabetes, high-protein diets reduced liver fat by up to 48 percent within six weeks. It did not matter whether the diet was mainly based on plant or animal protein.